articleTop 1% cited
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
AIDS · 2001 · Vol. 15(15) · pp. 1951–1957
Susan H. Eshleman✉(AIDS Clinical Trials Group)Martin Mracna(AIDS Clinical Trials Group)Laura Guay(Health and Human Development (2HD) Research Network)Martina Deseyve(Health and Human Development (2HD) Research Network)Shawn Cunningham(Fred Hutch Cancer Center)Mark Mirochnick(Health and Human Development (2HD) Research Network)Philippa Musoke(National Institutes of Health)Thomas R. Fleming(National Institutes of Health)Mary Glenn Fowler(Health and Human Development (2HD) Research Network)Lynne Mofenson(Fred Hutch Cancer Center)Francis Mmiro(AIDS Clinical Trials Group)J. Brooks Jackson(National Institutes of Health)
Abstract
NVP(R) was detected more frequently in infants than women following NVP prophylaxis, and different patterns of NVP(R) mutations were detected in women versus infants. NVP(R) was detected infrequently in infants with late HIV-1 infection. NVP-resistant HIV-1 faded from detection in women and infants over time.
HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and TreatmentNevirapineMedicineGenotypingTransmission (telecommunications)Viral loadHuman immunodeficiency virus (HIV)MutationVirologyPediatricsInternal medicine
MeSH terms
FemaleHumansInfantInfant, NewbornMutationPregnancyPregnancy Complications, InfectiousHIV-1HIV InfectionsInfectious Disease Transmission, VerticalReverse Transcriptase InhibitorsAnti-HIV AgentsNevirapineDrug Resistance, ViralHIV Reverse Transcriptase
Citations
420
FWCI
18.18
field-weighted impact
References
8
Percentile
100%
vs. same field & year
Citations per year
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.